Search - tctmd.com

Displaying 321 - 340 of 428

Sort: Relevancy | Date

News Conference News EuroPCR 2014

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Yael L. Maxwell

May 21, 2014

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

News Daily News

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

May 20, 2014

News Daily News

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Caitlin E. Cox

April 30, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Daily News

ARCTIC Analysis: Platelet Function Testing Does Not Enhance Secondary Prevention

Caitlin E. Cox

April 11, 2014

News Daily News

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

Yael L. Maxwell

April 10, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

Bleeding Common but Often Unreported in ACS Patients on Antiplatelet Therapy

L.A. McKeown

February 06, 2014

News Daily News

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Caitlin E. Cox

January 29, 2014

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

Advertisement

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ARCTIC Analysis: Platelet Function Testing Does Not Enhance Secondary Prevention

STEMI Patients with Large Thrombus Benefit from Low-dose Thrombolysis

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Bleeding Common but Often Unreported in ACS Patients on Antiplatelet Therapy

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content